Anti-CD38 (Daratumumab), Human IgG1 Antibody

Anti-CD38 (Daratumumab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a human IgG1 kappa monoclonal antibody that targets CD38, a type II transmembrane glycoprotein that is expressed on lymphoid cells, myeloid cells, and non-hematopoietic cells and performs several cell signaling functions. It is overexpressed on multiple myeloma cells. The antibody binds to CD38 and induces tumor cell death via diverse mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis. Antibody-dependent cellular cytotoxicity is mediated by the binding of the Fc region of the antibody with FcR of NK cells; complement-dependent cytotoxicity is mediated by the binding of the Fc region of the antibody with C1q, followed by the initiation of the complement cascade; antibody-dependent cellular phagocytosis is mediated by binding of the Fc region of the antibody with the FcR of the macrophage. The original drug received FDA approval in 2015 to treat multiple myeloma

Immunogen Sequence:Human CD38

Target Alternative Name:HuMax-CD 38, HuMax-CD38, JNJ-54767414, ADPRC1, ADPRC 1

Species Reactivities:Human

Tag Line:The biosimilar is a human monoclonal antibody that targets CD38 overexpressed on multiple myeloma cells and induces apoptosis via antibody and complement-dependent cell cytotoxicity. The original drug was FDA approved for the treatment of multiple myeloma

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:In vitro studies

Positive Control:/

Application And Usages:In vitro studies

Handling:The antibody solution should be gently mixed before use.